Cart: 0 items   Total: $0

Check Out

Corporate Information

About NuSep

NuSep (ASX: NSP) is a listed life sciences company that develops and sells products for the:

  • Therapeutic Plasma market;
  • IVF Clinical Market; and 
  • Research Consumables market.
 
NuSep has offices in Sydney, Singapore and Athens GA, USA.

With 30 years of experience in introducing and commercialising new technologies in biological separations, NuSep has forged a world class reputation for its innovative yet simple solutions to biological separation problems including the world's first:

  • IVF sperm separation using Electrophoresis; 
  • Therapeutic Plasma production using disposal manufacturing technology; and
  • 2 minute visualisation of Gel bands.



In short, NuSep has redefined the BioSeparations market through innovation and simplification.
NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

Corporate History

NuSep listed on the ASX in May 2007 having been spun out of Life Therapeutics Ltd in December 2006 as a free in species distribution. As part of this spin out, Life Therapeutics transferred the Gels and SpermSep technology to NuSep. In December 2006 each Life Therapeutics shareholder received 1 free NuSep share for each 20 Life Therapeutics shares that they held. NuSep has NO relationship to Life Therapeutics or its subsequent name change into an essentially mining company.

In 2008 NuSep completed the SpermSep safety and efficacy clinical study. This showed that the SpermSep was as safe and efficacious as the existing process. In late 2009 NuSep completed a capital raising and discovered the need for a low volume plasma fractionation plant in Singapore.

Since this time NuSep has been focused on developing its PrIME technology to meet this market niche of the Therapeutic Plasma market. Of recent times requests from IVF clinicians have highlighted the need to fast track the commercialisation of the SpermSep instrument. NuSep intends to use the funds raised from the March 2012 share options to complete the SpermSep project.

Technology History

NuSep traces its roots back to the pioneer biological separations development by Dr Joel Margolis and Dr Perry Manusu in the early 1970's. This productive and innovative partnership produced the world’s first gradient gel, the first micro gel and the first industrial scale electrophoresis separation system. NuSep owes a considerable scientific debt to these two talented scientists and is using this solid intellectual capital foundation to become the premier technology supplier in the BioSeparations market.

The work of Drs Margolis and Manusu have produced a number of world firsts:

Prior to 2006
  • First gradient gel in 1969;
  • First Highly crosslinked gel 1980;
  • First continuous flow membrane fraction system 1984;
  • First micro gel in 1988;
  • First solid wells in precast gels 1993;
  • First large scale gel manufacturing system 1995;
  • First micro membrane fractionation system 2005;
  • First electrical separation of sperm 2005;

After the NuSep Spinout in 2006
  • First SpermSep clinical trial at Westmead Fertility Centre 2008;
  • Launch of the ProteomeSep instrument 2010;
  • Launch of the nUView Gels 2010;
  • Launch of the ProteoIQ preoteomics software 2010;
  • Development of a disposable method to fractionate human plasma 2010;
  • Establishment of the world’s first plant in Singapore to manufacture plasma protein using the patented PrIME technology
  • Launch of long life Tris-Glycine Gels 2011.

From the outset, NuSep was founded as a life science company with a mission to redefine the Biological Separations market based on our novel technology. This has now produced both a novel method to separate human sperm for IVF and separation of Therapeutic Plasma products using a disposable production process.

NuSep will continue to provide the same high quality service and innovative products for biological separations recognised by scientists for over 30 years.


Vision

NuSep's vision is:

To be the Premier Technology Supplier in the BioSeparations market.

The accomplishment of this vision requires that  the Company must commercialise products that the customer requires at a price which is affordable to the customer but profitable for NuSep. This approach will allow NuSep to continue to innovate and grow to become a substantial player in the relevant markets it is involved in. The company’s vision emphasises the innovative and vibrant spirit and focussed drive which delivers new opportunities such as the PrIME based protein separation system now being installed in Singapore


Goals

NuSep has two primary goals which it is aiming to achieve.  These are:

  • To grow NuSep so that it has yearly sales of $100 million and $20 million in profit per annum within 5 years; and
  • To become an ASX Top 300 company.